Marco Orsini Federici

Eli Lilly (Italy) — Italy

Medicine · Health Sciences

16h-index2.3kcitations63works0.72yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Diabetes Management and Research(22), Diabetes Treatment and Management(21), Metabolism, Diabetes, and Cancer(19), Pancreatic function and diabetes(7), Diabetes and associated disorders(7)

Publications63 total

Improving outcomes with early and intensive metabolic control in patients with type 2 diabetes: a long-term modeling analysis of clinical and cost outcomes in Italy
Journal of Diabetes & Metabolic Disorders·2025· 1 citedOpen Access
Bridge the Inference Gaps of Neural Processes via Expectation Maximization
arXiv (Cornell University)·2025· 1 citedOpen Access
The real-world observational prospective study of health outcomes with dulaglutide and liraglutide in type 2 diabetes patients (TROPHIES): resource use and costs of treatment in clinical practice in France, Germany, and Italy
Journal of Medical Economics·2024Open Access
Simulation-based Inference with the Generalized Kullback-Leibler Divergence
arXiv (Cornell University)·2023Open Access
The Real‐World Observational Prospective Study of Health Outcomes with Dulaglutide and Liraglutide in Type 2 Diabetes Patients ( <scp>TROPHIES</scp> ): Final patient‐reported outcomes at 24 months
Diabetes Obesity and Metabolism·2023· 7 citedOpen Access
Latent Representation and Simulation of Markov Processes via Time-Lagged Information Bottleneck
arXiv (Cornell University)·2023Open Access
The real‐world observational prospective study of health outcomes with dulaglutide and liraglutide in patients with type 2 diabetes ( <scp>TROPHIES</scp> ): Final, 24‐month analysis of time to first significant treatment change, treatment persistence and clinical outcomes
Diabetes Obesity and Metabolism·2023· 5 citedOpen Access
Two for One: Diffusion Models and Force Fields for Coarse-Grained Molecular Dynamics
Journal of Chemical Theory and Computation·2023· 77 citedOpen Access
Author response for "The real‐world observational prospective study of health outcomes with dulaglutide and liraglutide in patients with type 2 diabetes (&lt;scp&gt;TROPHIES&lt;/scp&gt;): Final, 24‐month analysis of time to first significant treatment change, treatment persistence and clinical outcomes"
2023
Author response for "The real‐world observational prospective study of health outcomes with dulaglutide and liraglutide in patients with type 2 diabetes (&lt;scp&gt;TROPHIES&lt;/scp&gt;): Final, 24‐month analysis of time to first significant treatment change, treatment persistence and clinical outcomes"
2023
On the Effectiveness of Hybrid Mutual Information Estimation
arXiv (Cornell University)·2023Open Access
The Real-World Observational Prospective Study of Health Outcomes with Dulaglutide &amp; Liraglutide in Type 2 Diabetes Patients (TROPHIES): final 24-month primary endpoint analysis
Diabetologie und Stoffwechsel·2023
Two for One: Diffusion Models and Force Fields for Coarse-Grained Molecular Dynamics
arXiv (Cornell University)·2023· 10 citedOpen Access
The <scp>Real‐World</scp> Observational Prospective Study of Health Outcomes with Dulaglutide and Liraglutide in Patients with Type 2 Diabetes ( <scp>TROPHIES</scp> ): Patient disposition, clinical characteristics and treatment persistence at 12 months
Diabetes Obesity and Metabolism·2022· 11 citedOpen Access
Author response for "The &lt;scp&gt;Real‐World&lt;/scp&gt; Observational Prospective Study of Health Outcomes with Dulaglutide and Liraglutide in Patients with Type 2 Diabetes ( &lt;scp&gt;TROPHIES&lt;/scp&gt; ): Patient disposition, clinical characteristics and treatment persistence at 12 months"
2022
Compositional Mixture Representations for Vision and Text
arXiv (Cornell University)·2022Open Access
Author response for "The &lt;scp&gt;Real‐World&lt;/scp&gt; Observational Prospective Study of Health Outcomes with Dulaglutide and Liraglutide in Patients with Type 2 Diabetes ( &lt;scp&gt;TROPHIES&lt;/scp&gt; ): Patient disposition, clinical characteristics and treatment persistence at 12 months"
2022
The Real-World Observational Prospective Study of Health Outcomes with Dulaglutide &amp; Liraglutide in Type 2 Diabetes Patients (TROPHIES): 12-month data analysis
Diabetologie und Stoffwechsel·2022
POSC359 The Real-World Observational Prospective Study of Health Outcomes with Dulaglutide &amp; Liraglutide in Type 2 Diabetes Patients (TROPHIES): Patient Reported Outcomes at 12-Months
Value in Health·2022
Towards Lightweight Controllable Audio Synthesis with Conditional\n Implicit Neural Representations
arXiv (Cornell University)·2021· 2 citedOpen Access
page 1 of 4Next →

Frequent Co-authors

M. Massi Benedetti(13), Kristina S. Boye(12), Bruno Guerci(9), Francesco Giorgino(9), Elke Heitmann(9), Luis‐Emilio García‐Pérez(9), Jérémie Lebrec(8), Hélène Sapin(8), Anne Dib(7), Martin Füchtenbusch(7), Kirsi Norrbacka(6), Valentina Canonico(5), Massimo Massi‐Benedetti(4), Giovanni Biricolti(4), R. Gentilella(4), Vincenzo Bàrbera(4), Luca Di Lullo(4), Giovanni Otranto(4), Alberto Santoboni(4), P.G. Fabietti(3)